Clinical Trial Finds Solriamfetol Significantly Improves Alertness and Performance for Early Morning Shift Workers Facing Shift Work Disorder

A groundbreaking clinical trial led by researchers at Mass General Brigham has revealed that solriamfetol, a wake-promoting medication currently used for narcolepsy and sleep apnea, significantly improves alertness and functional performance in individuals working early morning shifts. The study, published in the prestigious journal NEJM Evidence, represents the first clinical trial to specifically target the unique challenges faced by the millions of workers who begin their duties between 3:00 a.m. and 7:00 a.m. While overnight shift work has long been the focus of circadian rhythm research, the "early bird" shift—the most common non-standard work schedule in the modern economy—has remained largely overlooked by medical science until now.

Shift work disorder (SWD) is a chronic condition characterized by excessive sleepiness during work hours and insomnia when attempting to sleep during the day. For those starting work in the pre-dawn hours, the biological toll is immense. These workers are forced to perform during the "circadian trough," a period in the early morning when the human body’s internal temperature is at its lowest and the drive for sleep is at its physiological peak. The new findings suggest that solriamfetol, marketed under the brand name Sunosi, could provide a vital lifeline for these essential workers, enhancing not only their productivity but also their safety and overall quality of life.

The Biological Conflict of the Early Morning Shift

The human body operates on a roughly 24-hour internal clock known as the circadian rhythm, governed by the suprachiasmatic nucleus in the brain. This clock regulates everything from hormone release to cognitive function. For the vast majority of the population, the brain is biologically programmed to be in a state of deep restorative sleep between the hours of 2:00 a.m. and 6:00 a.m. When an individual wakes up at 3:30 a.m. to commute to a warehouse, a hospital, or a transportation hub, they are effectively fighting millions of years of evolutionary biology.

"People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep," explained first author Kirsi-Marja Zitting, PhD, an investigator with the Division of Sleep and Circadian Medicine at Mass General Brigham. This misalignment creates a "double burden." Not only must the worker fight intense, brain-fogging sleepiness while on the job, but they often find it difficult to achieve restorative sleep later in the morning or afternoon when the sun is up and the body’s internal signals are screaming for wakefulness.

Approximately 20% to 25% of the global workforce operates on non-traditional schedules. Many of these individuals do not categorize themselves as "shift workers" in the traditional sense, often viewing their 4:00 a.m. start time as merely an "early morning" routine. However, the medical reality is that these schedules induce the same physiological disruptions as graveyard shifts. Without adequate intervention, these workers face a heightened risk of chronic health issues, including cardiovascular disease, metabolic syndrome, and clinical depression.

Methodology of the Mass General Brigham Clinical Trial

To address the gap in treatment options for this specific demographic, the research team conducted a rigorous, randomized, double-blind, placebo-controlled trial. The study enrolled 78 adults who were diagnosed with shift work disorder and held regular early morning work schedules.

The trial was structured over a four-week period. Participants were randomly assigned to receive either a daily dose of solriamfetol or a placebo on their scheduled workdays. To ensure the accuracy of the results, the researchers employed several standardized metrics to evaluate wakefulness and cognitive performance:

1. Maintenance of Wakefulness Test (MWT): This is the gold-standard objective measure of a person’s ability to remain awake in a dark, quiet, and low-stimulation environment. Participants were tested during hours that mirrored their actual early morning work shifts.
2. Clinical Global Impression of Change (CGI-C): This scale allowed both the participants and the supervising clinicians to rate the overall improvement in the patient’s condition relative to their baseline at the start of the study.
3. Functional Outcomes of Sleep Questionnaire (FOSQ-10): This metric was used to determine how the medication affected the participants’ ability to perform daily activities and tasks.

The participants were otherwise healthy adults, ensuring that the results were not skewed by underlying comorbidities, though the researchers noted that future studies would need to look at broader populations.

Key Findings: Improved Alertness and Work Performance

The results of the four-week trial were definitive. Participants who were administered solriamfetol demonstrated a statistically significant increase in their ability to remain awake compared to the placebo group. On the Maintenance of Wakefulness Test, those taking the drug were able to stay alert for longer durations during the simulated early morning hours, effectively pushing through the circadian trough that usually leads to "microsleeps" or severe cognitive lapses.

Beyond the laboratory measurements, the real-world implications were reported by the workers themselves. Participants in the solriamfetol group reported feeling more "present" and capable during their shifts. They noted improvements in their concentration and a reduction in the "heavy-lidded" exhaustion that often plagues the final hours of an early morning shift.

Senior author Charles A. Czeisler, PhD, MD, chief of the Division of Sleep and Circadian Medicine at Mass General Brigham, highlighted the clinical significance of these improvements. "The improvement we saw is clinically meaningful," Czeisler stated. "These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life."

One of the most promising aspects of solriamfetol discovered during the trial was its duration of action. Unlike some traditional stimulants that can cause a "crash" or linger in the system so long that they prevent sleep later in the evening, solriamfetol appeared to provide a sustained window of alertness that aligned well with the demands of an early morning shift without sabotaging the worker’s next sleep cycle.

Safety and the Economic Impact of Sleep-Deprived Labor

The safety of the medication is a primary concern for clinicians. In this trial, solriamfetol was generally well-tolerated, consistent with its previous approvals for narcolepsy and obstructive sleep apnea. While some medications used to treat SWD, such as modafinil, have been effective for overnight workers, they are not always ideal for early morning workers who may need to sleep earlier in the evening to prepare for the next day’s 3:00 a.m. wake-up call.

The societal and economic implications of untreated shift work disorder are staggering. Fatigue-related productivity losses cost the U.S. economy an estimated $136 billion annually. In high-stakes industries such as healthcare, aviation, and heavy machinery operation, the "biological cost" mentioned by Dr. Czeisler can manifest as life-threatening errors.

Early morning shift workers include nurses handing over patient care, pilots flying the first leg of a journey, and truck drivers delivering essential goods. When these individuals suffer from SWD, the risk of workplace injuries and vehicular accidents increases exponentially. By providing a pharmacological tool to stabilize alertness, the medical community can potentially reduce the frequency of these incidents.

Contextual Analysis: Why Solriamfetol Differs from Existing Treatments

Solriamfetol is a dual dopamine and norepinephrine reuptake inhibitor (DNRI). Unlike traditional amphetamines, which trigger a massive release of neurotransmitters, solriamfetol works by preventing the reabsorption of dopamine and norepinephrine, thereby maintaining higher levels of these wake-promoting chemicals in the synaptic cleft. This mechanism of action is generally associated with a lower potential for abuse and a more stable "steady-state" of alertness.

Historically, the treatment for shift work disorder has relied heavily on "sleep hygiene" and caffeine. However, sleep hygiene—such as using blackout curtains or avoiding blue light—is often insufficient to overcome the sheer power of the circadian drive for sleep at 4:00 a.m. Caffeine, while ubiquitous, has a short half-life and often leads to jitteriness and a subsequent "caffeine crash" that can impair performance mid-shift.

The Mass General Brigham study suggests that solriamfetol offers a more targeted neurological intervention. By specifically addressing the wakefulness deficits in early morning workers, it fills a therapeutic void that has existed since the formal recognition of shift work disorder as a medical condition.

Chronology of Research and Future Directions

The journey toward this clinical trial began years ago as sleep scientists recognized that the "early morning" cohort was a "missing middle" in circadian research. While the 2021 start of the trial (NCT04788953) marked a formal turning point, the conceptual framework was built on decades of work by Dr. Czeisler and his colleagues on the impact of light and timing on human performance.

The four-week duration of this trial serves as a "proof of concept." The researchers have been quick to emphasize that while the results are encouraging, the long-term effects of daily solriamfetol use for SWD require further investigation. Specifically, researchers want to ensure that the medication does not lead to long-term changes in sleep architecture or cardiovascular health over months or years of use.

The research team is already moving into the next phase of their investigation. They are currently enrolling participants for a follow-up clinical trial that will focus on overnight shift workers. By comparing the efficacy of solriamfetol across different types of non-standard shifts, the researchers hope to secure broader regulatory approval and provide comprehensive guidelines for clinicians prescribing the drug.

Conclusion: Supporting the Essential Workforce

The Mass General Brigham study is more than just a validation of a specific drug; it is a recognition of a segment of the workforce that has long suffered in silence. Early morning workers are the gears that keep society running while the rest of the world sleeps. They are the bakers, the bus drivers, the emergency room staff, and the logistics coordinators who ensure that the modern world is ready for the 9-to-5 population.

"Shift workers are essential to how our society functions, yet they often pay a hidden biological cost," Dr. Czeisler noted. "This study shows we can do better for them."

As the medical community continues to unravel the complexities of the human circadian system, the hope is that a combination of better scheduling practices, light therapy, and targeted pharmacological interventions like solriamfetol will allow these workers to maintain their health and safety. For now, the findings in NEJM Evidence provide a clear path forward, offering a scientifically backed solution to the profound fatigue that has long been considered an unavoidable part of the job for the world’s early morning workers.